Related Experiment Video
Updated: Jul 3, 2026
03:52
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Target population for clinical trials on sarcopenia
1Department of Aging and Geriatric Research, University of Florida - Institute on Aging, Gainesville, FL 32611, USA. mcesari@aging.ufl.edu
The Journal of Nutrition, Health & Aging
|July 11, 2008
Summary
Sarcopenia, the age-related loss of muscle, is influenced by many factors. Understanding these factors is crucial for designing effective clinical trials to study aging and muscle decline.
Area of Science:
- Gerontology
- Muscle Physiology
- Clinical Trial Design
Background:
- Sarcopenia is the progressive decline in muscle mass, strength, and function associated with aging.
- It is a consequence of aging, not classified as a disease.
- Numerous demographic, biological, and clinical factors impact skeletal muscle health.
Purpose of the Study:
- To identify key factors that can bias results in sarcopenia clinical trials.
- To highlight the challenges in isolating the aging process in sarcopenia research.
- To emphasize the urgent need for well-designed clinical trials on sarcopenia.
Main Methods:
- Review of existing literature on sarcopenia and aging.
- Analysis of factors influencing muscle mass, strength, and function.
- Identification of potential confounders in clinical trial participant selection.
Main Results:
- Sarcopenia research is limited by difficulties in controlling for multiple interconnected factors.
- Demographic, biological, and clinical variables significantly affect muscle health in aging.
- Potential sources of bias in clinical trials include these multifactorial influences.
Conclusions:
- Clarifying controversial aspects of sarcopenia is essential for advancing research.
- Careful consideration of influencing factors is necessary for robust clinical trial design.
- Further research is needed to understand and address sarcopenia as a hallmark of aging.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...